GLP-1 receptor agonists × glycemic control

TrialDiabetes, obesity & metabolism2022

Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.

Ele Ferrannini et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 351 people · 2022

No range given

Reported higher glycemic control, no range given

+35.0percentage points

As reported

difference 35 %, no interval

One number in the abstract

the abstract, start to end

sensitivity increased by a median 35% (p = .0032 vs.

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
35
GLP-1 receptor agonistsGlycemic control
1 / 3

5 papers cite it

2022
2023
2024
2025
this papertrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 35257461